Patients With Colorectal Cancer Report Inadequate Nutritional Support in Survey of Survivors
A cross-sectional survey of patients with CRC revealed a lack of nutritional advice, as well as awareness of its availability.
Colorectal Cancer
Disparities of Colorectal Liver Metastases Treatment and Survival Among Ethnic Groups in California
A retrospective cohort study explored whether the low rate of resection for colorectal liver metastases is associated with lower survival rates among Black patients with CRC.
Immunotherapy Plus Radiotherapy After Surgery Improves OS in Tumors With Brain Metastases, Study Finds
Study found adding immunotherapy to radiotherapy significantly improved OS after definitive surgery for primary tumor in patients with brain metastasis.
Geriatric Nutritional Risk Index Predictive of Outcomes Following Colorectal Cancer Surgery
A retrospective study sought to determine the accuracy of the GNRI in predicting postoperative complications and overall survival in elderly patients with colorectal cancer.
Central Venous Catheter Insertion in Colorectal Cancer Patients, PICC or PC?
[Cancer Management and Research] This study explores the preference of colorectal cancer patients for port catheters (PCs) through comparing the costs and complications between peripherally inserted central venous catheters and PCs.
Reminder + FIT Test Cost-Effective for Promoting CRC Screening
Reminder + FIT reduced costs per additional Medicaid enrollee screened compared with reminder only.
ACE Inhibitors Associated With Lower Colorectal Cancer Risk in Large Cohort Study
A team of investigators sought to determine if the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers were associated with the development of colorectal cancer.
No Benefit of Surgery Over Endoscopic Resection for T1 Colorectal Cancer
A team of investigators conducted a meta-analysis and systematic review to compare outcomes of endoscopic resection vs surgery for T1 colorectal cancer.
Keytruda Approved as First-Line Treatment of MSI-H or dMMR Colorectal Cancer
The FDA has approved Keytruda (pembrolizumab; Merck), a programmed death receptor-1 -blocking antibody, as monotherapy for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Complications After Colonoscopy Up for Those Aged ≥75
Other factors associated with risk include anemia, cardiac arrhythmia, hypertension, smoking history, obesity
-
Loading...
-
Loading...
Next post in Colorectal Cancer
